-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatitis C virus (HCV) is one of the main causes of liver disease worldwide.
diabetes
This study aims to evaluate the effect of anti-HCV direct-acting antiviral (DAA) treatment on long-term blood glucose control in patients with chronic hepatitis C (CHC) or cirrhosis of type 2 diabetes (HCV/T2DM) .
To evaluate the effect of anti-HCV direct-acting antiviral (DAA) treatment on long-term blood glucose control in patients with chronic hepatitis C (CHC) or cirrhosis of type 2 diabetes (HCV/T2DM)
The study included 182 HCV/T2DM patients who had achieved virus clearance through DAA treatment.
HbA1c levels at each time node of the two groups of patients
HbA1c levels at each time node of the two groups of patientsAt baseline, the average value of glycosylated hemoglobin (HbA1c) in the total study population was 7.
The HbA1c variant evaluation showed that compared with the baseline of CHC patients, blood glucose control was significantly improved at all time points after treatment.
Using DAA-based programs to cure HCV can significantly and continuously improve the blood glucose control of type 2 diabetic patients with chronic hepatitis.
Original source:
Cacciola Irene,Russo Giuseppina,Filomia Roberto et al.
org/10.
1111/liv.
14905" target="_blank" rel="noopener">Over time evaluation of glycaemic control in direct -acting-antiviral treated HCV / diabetic individuals with chronic hepatitis or with cirrhosis in this message